24,748 Edwards Lifesciences Corporation $EW Shares Sold by Inscription Capital LLC

Inscription Capital LLC trimmed its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 81.9% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 5,466 shares of the medical research company’s stock after selling 24,748 shares during the quarter. Inscription Capital LLC’s holdings in Edwards Lifesciences were worth $472,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also made changes to their positions in the company. BlackRock Inc. acquired a new position in shares of Edwards Lifesciences during the 2nd quarter worth about $5,318,092,000. Varma Mutual Pension Insurance Co bought a new stake in Edwards Lifesciences during the 2nd quarter valued at approximately $11,168,000. Conway Capital Management Inc. bought a new stake in Edwards Lifesciences during the 2nd quarter valued at approximately $954,000. Commerce Bank acquired a new stake in Edwards Lifesciences in the 2nd quarter valued at approximately $3,121,000. Finally, Assenagon Asset Management S.A. grew its holdings in Edwards Lifesciences by 50.0% in the 3rd quarter. Assenagon Asset Management S.A. now owns 2,719,271 shares of the medical research company’s stock valued at $234,727,000 after buying an additional 906,345 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Edwards Lifesciences

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: Edwards reported Q3 sales growth of 11.2% to $1.72 billion, with adjusted earnings and revenue beating estimates. TMTT sales rose 45.6% and TAVR sales grew 8.8%; the company raised its sales outlook and set adjusted full-year EPS guidance of $2.97–$3.05. Edwards Q3 earnings call highlights
• Positive Sentiment: PROGRESS Trial results found TAVR outperformed active surveillance for at-risk patients with moderate aortic stenosis, including fewer combined death or heart-failure outcomes. The findings could support earlier use of the procedure and expand Edwards’ potential market. Trial data points to earlier TAVR use
• Positive Sentiment: Analysts lifted price targets following the results: UBS raised its target to $118 and JPMorgan to $120, while Piper Sandler reaffirmed its buy-equivalent rating with a $115 target. The latest target increases and reaffirmations add to bullish sentiment. UBS reaffirms buy rating Piper Sandler keeps buy rating
• Negative Sentiment: Management has acknowledged that more competition is coming in TAVR, a potential pressure on market share and future growth, although the recent results and trial data provide positive offsets. CEO comments on TAVR competition

Wall Street Analysts Forecast Growth

Several research analysts have commented on EW shares. Jefferies Financial Group lifted their price target on Edwards Lifesciences from $102.00 to $105.00 and gave the stock a “buy” rating in a research report on Friday, July 24th. Deutsche Bank Aktiengesellschaft set a $104.00 price objective on Edwards Lifesciences in a research report on Tuesday, October 27th. Rothschild & Co Redburn raised their price objective on shares of Edwards Lifesciences from $99.00 to $102.00 and gave the stock a “buy” rating in a research note on Monday, July 27th. JPMorgan Chase & Co. boosted their target price on shares of Edwards Lifesciences from $105.00 to $120.00 and gave the stock an “overweight” rating in a research report on Thursday. Finally, The Goldman Sachs Group upped their target price on shares of Edwards Lifesciences from $98.00 to $102.00 and gave the company a “buy” rating in a research note on Tuesday, July 14th. Twenty-three research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and an average target price of $108.88.

Insider Transactions at Edwards Lifesciences

In other news, VP Daniel Lippis sold 619 shares of the business’s stock in a transaction that occurred on Thursday, October 8th. The stock was sold at an average price of $85.65, for a total transaction of $53,017.35. Following the sale, the vice president directly owned 40,034 shares in the company, valued at approximately $3,428,912.10. The trade was a 1.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Annette Brüls sold 2,644 shares of the company’s stock in a transaction on Friday, August 28th. The shares were sold at an average price of $89.98, for a total value of $237,907.12. Following the completion of the transaction, the vice president owned 17,984 shares of the company’s stock, valued at $1,618,200.32. The trade was a 12.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 5,045 shares of company stock valued at $451,596. 0.31% of the stock is owned by corporate insiders.

Edwards Lifesciences Stock Up 1.1%

EW stock opened at $101.91 on Friday. Edwards Lifesciences Corporation has a twelve month low of $74.66 and a twelve month high of $104.17. The company has a market cap of $58.68 billion, a PE ratio of 57.58, a price-to-earnings-growth ratio of 2.67 and a beta of 0.85. The business’s 50-day simple moving average is $88.92 and its 200 day simple moving average is $85.78. The company has a quick ratio of 3.77, a current ratio of 4.60 and a debt-to-equity ratio of 0.05.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Wednesday, November 4th. The medical research company reported $0.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.06. The firm had revenue of $1.72 billion for the quarter, compared to analyst estimates of $1.68 billion. Edwards Lifesciences had a return on equity of 16.06% and a net margin of 15.30%. The company’s quarterly revenue was up 10.5% compared to the same quarter last year. During the same period in the previous year, the company posted $0.67 earnings per share. On average, research analysts anticipate that Edwards Lifesciences Corporation will post 3.02 earnings per share for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on therapies for structural heart disease and critical care. Its products include transcatheter and surgical heart valves, as well as technologies used to monitor patients during intensive care and surgery.

The company traces its origins to 1958, when engineer Lowell Edwards and surgeon Albert Starr began developing an artificial heart valve. Their work led to the Starr-Edwards valve, introduced in 1960. Edwards Lifesciences is headquartered in Irvine, California, and serves clinicians and patients around the world.

Its structural heart portfolio includes transcatheter aortic valve replacement (TAVR) systems and therapies addressing mitral and tricuspid valve disease.